Αναζήτηση Δραστικών

NARATRIPTAN

Εμπορικές Ονομασίες

  • DRUGBANK - Naratriptan
  • indication:

    For the acute treatment of migraine attacks with or without aura in adults.

  • pharmacology:

  • mechanism:

    Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.

  • toxicity:

    Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.

  • absorprion:

    Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.

  • halflife:

    5-8 hours

  • roouteelimination:

  • volumedistribution:

    * 170 L

  • clearance:

    * 6.6 mL/min/kg